Biotechnology company focused on developing gene therapies for severe genetic diseases and cancer.
bluebird bio, Inc., a prominent biotechnology company based in Cambridge, Massachusetts, is dedicated to pioneering transformative gene therapies for severe genetic diseases. The company focuses on researching, developing, and commercializing innovative treatments that aim to significantly improve the lives of patients.
Among its portfolio of product candidates, bluebird bio is advancing betibeglogene autotemcel for transfusion-dependent ß-thalassemia, lovotibeglogene autotemcel for sickle cell disease (SCD), and elivaldogene autotemcel for cerebral adrenoleukodystrophy. These therapies represent cutting-edge approaches in genetic medicine, aiming to address critical unmet needs in rare and debilitating conditions.
The company's robust clinical study program includes multiple trials such as HGB-205, HGB-206, and HGB-210, evaluating lovo-cel's safety and efficacy in treating SCD, and HGB-204, HGB-205, HGB-207, and HGB-212, assessing beti-cel for ß-thalassemia treatment. These studies underscore bluebird bio's commitment to advancing the field of gene therapy through rigorous research and development.
Established in 1992 as Genetix Pharmaceuticals, Inc., the company rebranded as bluebird bio, Inc. in September 2010. bluebird bio has forged strategic collaborations and license agreements with leading biotechnology firms such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc., enhancing its capabilities in delivering breakthrough therapies to patients globally.